IN 1996, A SMALL GROUP OF RESEARCHERS AND MANAGERS BEGAN EXPLORING THE IDEA OF CREATING A NEW BIOPHARMACEUTICAL COMPANY.
Actelion’s founders were drawn together by successful collaboration, complementary skills and a belief in their collective scientific ideas. Having performed pioneering research at Roche, to characterize endothelin – a powerful blood vessel constrictor – and its receptors, the Roche team set out, to discover and develop a new class of anti-hypertensive drugs, so-called endothelin receptor antagonists (ERAs).
When Roche decided not to pursue this class of drugs the founders seized the opportunity to realize their ambition. Taking personal risk with their own funding, Actelion’s founders walked away from security at Roche, and following some additional financing, they negotiated the licensing of the compounds they had discovered and developed: tezosentan and bosentan.
Just a few years later, in April 2000, Actelion went public. Approximately one year later, shortly after a competitor’s ERA failed in development, in April 2001, tezosentan reported an unsuccessful study – and the share price plummeted. The founders’ commitment, however, did not waiver, they continued to develop their second ERA, bosentan. In December 2001, the initial risk was rewarded, as bosentan became Actelion’s first marketed product, Tracleer®.
Actelion was lifted into profitability in record time.
What made Actelion different was the deliberate decision to create its own discovery capability, to develop its own drugs and then to market them around the globe. The founders did not opt to pass the drugs along and quickly recoup their investment, but set about establishing a company with a clear ambition to find new drugs and treat more patients.
Over time, Actelion established a very active drug discovery and development organization, created a sales and marketing organization that spans the globe, including operations in Japan, and acquired four more products.
Actelion is a leader in the field of pulmonary arterial hypertension (PAH). Our portfolio of PAH treatments covers the spectrum of disease, from WHO Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous medications.
Although not available in all countries, Actelion has treatments approved by health authorities for a number of specialist diseases including Type 1 Gaucher disease, Niemann-Pick type C disease, Digital Ulcers in patients suffering from systemic sclerosis, and mycosis fungoides in patients with cutaneous T-cell lymphoma.
SAS (pronounced "sass") once stood for "statistical analysis system." It began at North Carolina State University as a project to analyze agricultural research. Demand for such software capabilities began to grow, and SAS was founded in 1976 to help customers in all sorts of industries – from pharmaceutical companies and banks to academic and governmental entities.
SAS – both the software and the company – thrived throughout the next few decades. Development of the software attained new heights in the industry because it could run across all platforms, using the multivendor architecture for which it is known today. While the scope of the company has spread across the globe, the encouraging and innovative corporate culture has remained the same.
Analytics solutions to manage and leverage big data in life sciences is the new standard proving global collaboration based on accurate clinical research information. Rapid clinical trial insights that let you accelerate promising programs or stop unproductive ones. And streamlined processes that get your products to market faster. SAS is the de facto standard for clinical trials data analysis and reporting, and electronic submissions to regulatory authorities, such as the FDA. Our life sciences solutions include:
Support for CDISC. Standardize your clinical trials data and validate its adherence.
Risk-based monitoring. Optimize the scheduling of site visits and oversight by analyzing site and study data. Use advanced analytics to identify potential risks early enough to proactively address them.
Statistical analysis and reporting. Access and analyze clinical trials data to support clinical development decisions and submissions.
At wega, the customer's business targets are our challenge.
Our goal is to help customers successfully implement business objectives, thereby leveraging their competitive advantage. We offer a full spectrum of competencies ranging from Software Solution Engineering, Consulting, DBA Services, through to Project Management and support staffing of projects.
With over a decade of experience in the market, wega has established a world-class presence in IT service provision and consultancy. We have an extensive portfolio of successfully managed projects, yielding the highest customer satisfaction.
We pride ourselves in establishing a solid track record of long-term collaboration with our clients, winning their full confidence and reaffirming our position as a highly demanded strategic partner.
With about 30 emloyees and a large network of specialized freelancers, wega has the capacity and resourcefulness to implement larger projects effectively and efficiently.
wega Informatik was founded in 1993 in Basel, Switzerland as an IT service provider in the area of Electronic Data Processing (EDP). Since its foundation, wega has evolved into one of the leading Business and IT consultancy companies in the area
BaselArea.swiss is the office for promoting innovation and inward investment for the northwest cantons of Basel-Stadt, Basel-Landschaft and Jura. It grew out of the merger of the three organizations BaselArea, i-net innovation networks switzerland and the China Business Platform in 2016.
BaselArea.swiss today employs 18 people and has an annual budget of 3.6 million francs, which is borne by the three cantons and the State Secretariat for Economic Affairs (SECO).
The core function of BaselArea.swiss is to promote the strengths of the Basel region as a centre for business and to support both Swiss and foreign entrepreneurs and companies in the implementation of their innovation and business projects in the region.
The main focus of the services provided by BaselArea.swiss is on the sustained development and maintenance of a network of qualified decision makers, innovators, experts and disseminators. On the basis of this network, BaselArea.swiss provides clients with targeted access to knowledge and specialist know-how.
Further information about BaseArea.swiss- LINK
The life sciences industry is one of the key sectors of the 21st century. Huge technological advances, for example in genome sequencing, the development of highly efficient methods of gene manipulation and also breakthroughs in stem-cell research, have led to groundbreaking scientific discoveries. The growing digitalization of the healthcare sector also promises enormous advances in diagnostics and synthetic biology right through to completely new and increasingly also personalized approaches to medical treatment.
Further information about BaselArea.swiss Life Sciences - LINK
Document IT is an international operating company that represents an amalgamation of long-established associations and growing complementary experience. Document IT UK was founded in 1999, Document IT Switzerland in 2013 and Document IT BeNeLux in 2014. In 2015 we created entities in Denmark and opened our outsourcing center in Delhi, India.
Document IT has a specific focus on what we consider vital competencies of the Life Sciences IT industry of today: Quality Management, Project Management and Business Analysis. We believe that providing these skills and services from within a supported framework and knowledge base will strengthen the likelihood of success for projects and IT departments alike. We actively engage with and seek out new partners and associations to expand and nurture our growing network.
This model means we can take advantage of a talent, skills and experience pool that is both flexible, stable and supported to provide a strong and somewhat unique offering to the life sciences industry. Currently, Document IT has established entities in Denmark, India, Switzerland, the Netherlands and the United Kingdom.
LYO-X offers Quantitative Systems Pharmacology services. We are specialised in the preclinical and clinical development of novel therapeutic approaches including antibodies, antibody drug conjugates (ADC), gene therapies and cell based therapies. We serve our customers, highly innovative Biotech companies and global Pharma companies, here in Basel and worldwide. Quantitative Systems Pharmacology are computer models that describe the drug kinetics, mechanism of action and the effect on disease progression. These models serve to predict the drug properties including the effect in human. This allows our customers to better design drugs, select best candidates and predict early the therapeutic window in patients. We also use Quantitative Systems Pharmacology to tailor therapies based on the patients characteristics. With this LYO-X is offering the expertise and key technology for the development of Personalised Medicines.